⌕
Genmab · GMAB · Nasdaq
Tenet — · insufficient data
Compare
$51.96+0.76%At close
$51.96+0.39 (+0.76%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Genmab (GMAB) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is GMAB's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Globe News WireNov 11, 2026 · 15:43 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; November 11, 2026 - Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discl…

GMAB −1.1% todayRead at source ↗
● GlobeNewsWireNov 10, 2026 · 15:32 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; November 10, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 164,828 shares as a consequence of the exercise of employee warrants. The increase is effected wi…

GMAB −1.1% todayRead at source ↗
● Seeking AlphaNov 5, 2026 · 17:54 ET
Genmab A/S (GMAB) Q3 2026 Earnings Call Transcript

Genmab A/S (GMAB) Q3 2026 Earnings Call Transcript…

GMAB −1.1% todayRead at source ↗
● MarketBeatNov 5, 2026 · 15:15 ET
What Genmab A/S (GMAB) Said on Its Q3 Earnings Call

Genmab A/S NASDAQ: GMAB reported 22% revenue growth for the first nine months of 2026 and said it expects full-year revenue to land in the upper part of its existing guidance range, as sales of EPKINLY and royalty income…

GMAB −1.1% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting

Media Release COPENHAGEN, Denmark; November 4, 2026     Twenty-two abstracts underscore the versatility of epcoritamab as monotherapy and in combination across multiple disease subtypes and in earlier lines of therapy Si…

GMAB −1.1% todayRead at source ↗
● CNBCNov 3, 2026 · 04:35 ET
A little-known biotech's high-stakes cancer bet just paid off and its shares doubled

Genmab shares have doubled in three months after three successful Phase 3 cancer drug trials in October. The Danish biotech is using royalty income from drugs such as Darzalex to fund a shift toward owning more of the me…

GMAB −1.1% todayRead at source ↗
● Seeking AlphaOct 28, 2026 · 17:30 ET
Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcript

Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcript…

GMAB −1.1% todayRead at source ↗
● MarketBeatOct 28, 2026 · 17:05 ET
Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches

Genmab A/S NASDAQ: GMAB said three positive Phase III readouts across lymphoma, ovarian cancer and head and neck cancer could support multiple potential product launches beginning in 2027, as the company seeks to increas…

GMAB −1.1% todayRead at source ↗
● BenzingaOct 28, 2026 · 13:44 ET
Genmab Stock Hits 52-Week High - Here's Why

Genmab A/S (NASDAQ:GMAB) stock surged to a 52-week high after the company delivered positive topline findings from its global Phase 3 LiGeR-HN1 clinical trial evaluating petosemtamab, an investigational IgG1-bispecific a…

GMAB −1.1% todayRead at source ↗
● BarronsOct 28, 2026 · 13:21 ET
Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%

Genmab scores a ‘hat trick' with positive data for its experimental cancer drug, petosemtamab, Jefferies says.…

GMAB −1.1% todayRead at source ↗
● Business WireOct 28, 2026 · 09:41 ETCOMPANY'S OWN WORDS
Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced positive topline results from the global Phase 3 LiGeR-HN1 trial (NCT06525220) evaluating petosemtamab, an investigational IgG1-bispecific a…

GMAB −1.1% todayRead at source ↗
● Zacks Investment ResearchOct 26, 2026 · 12:26 ET
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy

INCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.…

GMAB −1.1% todayRead at source ↗
● BenzingaOct 26, 2026 · 11:08 ET
Genmab's Encouraging Oncology Data Boosts Investor Optimism

Biotechnology company Genmab A/S (NASDAQ:GMAB) delivered encouraging clinical updates for its investigational bispecific antibody petosemtamab across two major solid tumor types at the European Society for Medical Oncolo…

GMAB −1.1% todayRead at source ↗
● WSJOct 26, 2026 · 07:46 ET
Genmab Shares Jump After Positive Cancer Study Results

The Danish biotech said an experimental drug cut the risk of death and disease progression for ovarian-cancer patients in a late-stage clinical trial.…

GMAB −1.1% todayRead at source ↗
● GlobeNewsWireOct 26, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Media Release COPENHAGEN, Denmark; October 26, 2026 Median overall survival (OS) outcomes and encouraging anti-tumor activity observed with petosemtamab plus pembrolizumab in first-line (1L) recurrent or metastatic PD-L1…

GMAB −1.1% todayRead at source ↗
● Business WireOct 25, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal…

GMAB −1.1% todayRead at source ↗
● Business WireOct 24, 2026 · 07:01 ETCOMPANY'S OWN WORDS
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

COPENHAGEN, Denmark & WILMINGTON, Del.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab's investigational IgG1-bispecif…

GMAB −1.1% todayRead at source ↗

No upcoming events in the feeds.

NVDA20+3.1%
WDAY4+0.3%
CRWV3+7.0%

Article counts from the last market-wide feed page, across every symbol we track and not just GMAB · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.